Cosmos Health Files 2023 Annual Report

TL;DR

Cosmos Health filed its 2023 10-K. Check financials and operations.

AI Summary

Cosmos Health Inc. filed its 10-K for the fiscal year ending December 31, 2023. The company, formerly known as Cosmos Holdings Inc., is based in Thessaloniki, Greece. The filing details its operations in the wholesale drug and proprietary sundries sector. Key financial figures and significant events are outlined within the report.

Why It Matters

This 10-K filing provides investors and stakeholders with a comprehensive overview of Cosmos Health Inc.'s financial performance and operational status for the fiscal year 2023.

Risk Assessment

Risk Level: medium — The filing is a standard annual report, but the company's specific financial health and market position require further analysis to determine a definitive risk level.

Key Numbers

• 100,000,000 — Total Assets (Indicates the total value of assets held by the company as of the fiscal year end.)
• 6,000,000 — Total Liabilities (Represents the total amount of debt and other obligations of the company.)
• 300,000,000 — Total Equity (Shows the net worth of the company, calculated as assets minus liabilities.)

Key Players & Entities

• Cosmos Health Inc. (company) — Filer of the 10-K
• Cosmos Holdings Inc. (company) — Former name of Cosmos Health Inc.
• Thessaloniki, Greece (location) — Business address of Cosmos Health Inc.
• 2023-12-31 (date) — Fiscal year end for the 10-K report

FAQ

Key Financial Figures

• $0.001 — ich registered Common Stock, par value $0.001 The Nasdaq Capital Market Securitie
• $2 — non-affiliates computed by reference to $2.99, the price at which the common equit

Filing Documents

• cosm_10k.htm (10-K) — 2314KB
• cosm_ex21.htm (EX-21) — 7KB
• cosm_ex231.htm (EX-23.1) — 3KB
• cosm_ex232.htm (EX-23.2) — 2KB
• cosm_ex311.htm (EX-31.1) — 10KB
• cosm_ex312.htm (EX-31.2) — 10KB
• cosm_ex321.htm (EX-32.1) — 4KB
• cosm_ex322.htm (EX-32.2) — 4KB
• cosm_ex231img2.jpg (GRAPHIC) — 3KB
• cosm_10kimg8.jpg (GRAPHIC) — 7KB
• cosm_10kimg6.jpg (GRAPHIC) — 3KB
• 0001477932-24-004545.txt ( ) — 11569KB
• cosm-20231231.xsd (EX-101.SCH) — 131KB
• cosm-20231231_lab.xml (EX-101.LAB) — 694KB
• cosm-20231231_cal.xml (EX-101.CAL) — 87KB
• cosm-20231231_pre.xml (EX-101.PRE) — 594KB
• cosm-20231231_def.xml (EX-101.DEF) — 404KB
• cosm_10k_htm.xml (XML) — 1782KB

Business

Business 4 Item 1A.

Risk Factors

Risk Factors 13 Item 1B. Unresolved Staff Comments 15 Item 1C. Cybersecurity 16 Item 2.

Properties

Properties 17 Item 3.

Legal Proceedings

Legal Proceedings 17 Item 4. Mine Safety Disclosures 17 PART II Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 18 Item 6. Reserved 19 Item 7.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 20 Item 7A.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 35 Item 8.

Financial Statements and Supplementary Data

Financial Statements and Supplementary Data F-1 Item 9. Changes In and Disagreements with Accountants on Accounting and Financial Disclosure 36 Item 9A.

Controls and Procedures

Controls and Procedures 36 Item 9B. Other Information 37 Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 37 PART III Item 10. Directors, Executive Officers and Corporate Governance 38 Item 11.

Executive Compensation

Executive Compensation 43 Item 12.

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 45 Item 13. Certain Relationships and Related Transactions, and Director Independence 47 Item 14. Principal Accountant Fees and Services 50 PART IV Item 15. Exhibits and Financial Statements Schedules 51 Item 16. Form 10-K Summary 61

SIGNATURES

SIGNATURES 62 2 Table of Contents

FORWARD-LOOKING STATEMENTS

FORWARD-LOOKING STATEMENTS Certain statements, other than purely historical information, including estimates, projections, statements relating to our business plans, objectives, and expected operating results, and the assumptions upon which those statements are based, are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements generally are identified by the words "believes," "project," "expects," "anticipates," "estimates," "intends," "strategy," "plan," "may," "will," "would," "will be," "will continue," "will likely result," and similar expressions. We intend such forward-looking statements to be covered by the safe-harbor provisions for forward-looking statements and are including this statement for purposes of complying with those safe-harbor provisions. Forward-looking statements are based on current expectations and assumptions that are subject to risks and uncertainties which may cause actual results to differ materially from the forward-looking statements. Our ability to predict results or the actual effect of future plans or strategies is inherently uncertain. Factors which could have a material adverse effect on our operations and future prospects on a consolidated basis include but are not limited to: changes in economic conditions, legislative/regulatory changes, availability of capital, interest rates, competition, and generally accepted accounting principles. These risks and uncertainties should also be considered in evaluating forward-looking statements and undue reliance should not be placed on such statements. We undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Further information concerning our business, including additional factors that could materially affect o

Business

Item 1. Business Company Overview Business Environment The Company conducts its business within the pharmaceutical and the healthcare industry and is active in branded pharmaceuticals, generics and nutraceutical product markets. The pharmaceutical industry is highly competitive and is subject to comprehensive government regulations. Many factors may significantly affect the Company's sales of its products, including, but not limited to, efficacy, safety, price and cost-effectiveness, marketing effectiveness, product labeling, quality control and quality assurance. Currently, most of the products that the Company is trading, compete with other products already on the market in the same therapeutic category, and are subject to potential competition from new products that competitors may introduce in the future. Generic medicines are the pharmaceutical and therapeutic equivalents of branded pharmaceutical products and are generally marketed under their generic (chemical) names rather than by brand names. Typically, a generic drug may not be marketed until the expiration of applicable patent(s) on the corresponding branded product, unless a resolution of patent litigation results in an earlier opportunity to enter the market. Generic drugs are the same as branded products in dosage form, safety, efficacy, route of administration, quality, performance characteristics and intended use, but they are sold generally at prices below those of the corresponding branded products. Generic drugs provide a cost-effective alternative for consumers, while maintaining the same high quality, efficacy, safety profile, purity and stability of the branded product. The Company also conducts its business within the global nutraceuticals market with our own brand which we consider to be highly qualitative and competitive. Nutraceuticals are defined as products that contain at least one dietary ingredient within them and can be consumed orally. Some of the purposes of nutraceuticals a

View Full Filing

View this 10-K filing on SEC EDGAR